Pharma BD Deal Intelligence

Boehringer Ingelheim International GmbH / Synaffix B.V.

2025 · Licensing/Option · $1.3B · Complete

Boehringer Ingelheim licensed Synaffix's antibody-drug conjugate technology in January 2025, granting access to Synaffix's proprietary ADC platform for an agreed but undisclosed number of targets, with the first target nominated at signature. Synaffix, a Lonza company, is eligible for up to $1.3 billion in milestone payments plus royalties on net sales. The upfront payment was not disclosed. The deal supports Boehringer's ADC ambitions alongside its NBE Therapeutics subsidiary.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals  ·  Boehringer Ingelheim International GmbH deals